Posted on 01/03/2019 10:14:10 AM PST by Bob434
Cancer Research UK recruits first patients in trial to improve the early detection and diagnosis of different cancer types Study will use Owlstone Medical’s Breath Biopsy platform to identify breath biomarkers to detect and differentiate early-stage disease Study will recruit 1,500 patients at Addenbrooke’s Hospital, Cambridge
Cambridge, UK, January 3rd 2019: Owlstone Medical (or the “Company”), a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Cancer Research UK, today announces the clinical launch of the PAN Cancer trial for Early Detection of Cancer in Breath1, with the first patients now being recruited for the 1,500 patient study.
As previously announced on initiation of the collaboration, researchers in the trial are using Owlstone Medical’s2 Breath Biopsy® platform to collect samples, including healthy individuals as trial controls, to analyze volatile organic compounds (VOCs) in the breath. The trial aims to identify VOCs that can be used as breath-based biomarkers to detect and differentiate different cancer types, thereby improving early detection.
This approach holds great promise as cancer cells display altered metabolism even at the very earliest stage of disease, affecting the pattern of the VOCs exhaled. By identifying the changing pattern of VOCs early, Owlstone Medical’s Breath Biopsy technology could detect cancer at the earliest stage of disease, when treatments are more effective and more lives can be saved.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.